NCT03934372 2025-12-17
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Incyte Corporation
Phase 1/2 Recruiting
Incyte Corporation
Shenzhen TargetRx, Inc.
Jiangsu Hansoh Pharmaceutical Co., Ltd.